Skip to Content

Etoposide Injection

Last Updated: March 10, 2018
Status: Resolved

Etoposide Injection

Products Affected - Description
  • Toposar solution, Teva
    20 mg/mL, 5 mL multiple dose vial, 1 count (NDC 00703-5653-01)
    20 mg/mL, 25 mL multiple dose vial, 1 count (NDC 00703-5656-01)
    20 mg/mL, 50 mL multiple dose vial, 1 count (NDC 00703-5657-01)

    Etoposide solution, Accord
    20 mg/mL, 5 mL multiple dose vial, 1 count (NDC 16729-0114-31)
    20 mg/mL, 25 mL multiple dose vial, 1 count (NDC 16729-0114-08)
    20 mg/mL, 50 mL multiple dose vial, 1 count (NDC 16729-0114-11)

    Etoposide solution, Fresenius Kabi
    20 mg/mL, 5 mL multiple dose vial, 10 count (NDC 63323-0104-05)
    20 mg/mL, 25 mL multiple dose vial, 1 count (NDC 63323-0104-25)
    20 mg/mL, 50 mL multiple dose vial, 1 count (NDC 63323-0104-50)

Reason for the Shortage
    • Accord has etoposide on back order due to increased demand.
    • Fresenius Kabi has etoposide on back order due to increased demand.
    • Teva did not provide a reason for the current shortage.
    • Etoposide phosphate powder for injection (Etopophos) is unaffected by this shortage.
Available Products
  • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Accord has etoposide 20 mg/mL 5 mL, 25 mL, and 50 mL vials on intermittent back order and the company is releasing product as it becomes available.
    • Fresenius Kabi has etoposide 20 mg/mL 5 mL, 25 mL, and 50 mL vials on back order and the company estimates a release date of late-April 2018 for the 5 mL vials and early-April 2018 for the 20 mL and 50 mL vials. Check wholesalers for inventory.
    • Teva has Toposar 20 mg/mL 5 mL and 25 mL vials on allocation. The 50 mL vials are on back order and the company cannot estimate a release date.

Updated

March 10 and 6, February 26 and 6, January 24 and 10, 2018; December 21, 2017, University of Utah, Drug Information Service. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.

Hide